Montana Patent of the Month – March 2024
The battle against bacterial infections, particularly those caused by the notorious Pseudomonas aeruginosa, has been a long-standing challenge in the medical field. This opportunistic pathogen is a leading cause of severe pulmonary infections, especially in individuals with cystic fibrosis (CF). One of its most formidable weapons is its ability to form resilient biofilms, rendering it highly resistant to conventional antibiotics and immune responses.
Inimmune Corporation, a pioneering biotechnology company, has been granted a patent for a new approach to combating P. aeruginosa infections by targeting the Pf-family bacteriophage, a key player in biofilm formation. Their innovation lies in the development of an antiserum containing antibodies specific to the CoaB coat protein of the Pf-family bacteriophage.
The method involves immunizing animals or human subjects with a vaccine against the Pf-family bacteriophage. This vaccine consists of an immunogenic fragment of the CoaB coat protein conjugated to an immunogenic protein, along with a pharmaceutically acceptable carrier. By introducing this vaccine, the immune system is primed to produce antibodies tailored to neutralize the CoaB coat protein, thereby disrupting biofilm formation and rendering P. aeruginosa more susceptible to treatment.
What makes this approach particularly promising is its potential to address antibiotic-resistant strains of P. aeruginosa, which pose a significant threat in clinical settings. By combining the antiserum with antibiotics, it becomes possible to enhance the efficacy of existing treatments and overcome resistance mechanisms.
This method opens doors to new avenues of research and development in the field of infectious diseases. The specificity of the antibodies and the targeted approach offer a glimpse into the future of precision medicine, where tailored therapies hold the promise of better outcomes for patients.
Inimmune’s method represents a significant leap forward in the fight against P. aeruginosa infections. By harnessing the power of antibodies against the Pf-family bacteriophage, they are paving the way for more effective and personalized treatments, ultimately improving the lives of patients battling these challenging infections.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
